aziyo was created by highcape partners and tissue banks international with the mission of restoring health and mobility to the greatest number of patients. our vision for aziyo is to impact healthcare as the premier partner in innovation of new solutions that realize the potential of regenerative medicine. honoring the gift from those who selfishly give the precious gift of donation to those who receive it, we are committed to honoring the lives of these brave individuals and their families everyday. whether you need a traditional bone graft, a processed osteobiologic, or a custom musculoskeletal tissue product, aziyo is committed to innovating new solutions that help fulfill the promise of regenerative medicine. at aziyo, we foster a collaborative environment where we deliver best-in-class solutions and operational excellence to our customers each and every day.
Company profile
Ticker
ELUT
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AZIYO BIOLOGICS, INC.
SEC CIK
Corporate docs
Subsidiaries
Aziyo Med, LLC ...
IRS number
474790334
ELUT stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
11 Mar 24
8-K
Results of Operations and Financial Condition
7 Mar 24
424B3
Prospectus supplement
14 Feb 24
8-K
Departure of Directors or Certain Officers
2 Feb 24
S-8
Registration of securities for employees
25 Jan 24
8-K
Entry into a Material Definitive Agreement
12 Jan 24
8-K
Other Events
10 Jan 24
8-K
Other Events
27 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8 Dec 23
424B3
Prospectus supplement
5 Dec 23
Transcripts
ELUT
Earnings call transcript
2023 Q4
7 Mar 24
ELUT
Earnings call transcript
2023 Q2
14 Aug 23
ELUT
Earnings call transcript
2023 Q1
10 May 23
ELUT
Earnings call transcript
2022 Q4
22 Mar 23
ELUT
Earnings call transcript
2022 Q3
15 Nov 22
ELUT
Earnings call transcript
2022 Q2
13 Aug 22
ELUT
Earnings call transcript
2022 Q1
10 May 22
ELUT
Earnings call transcript
2021 Q4
4 Mar 22
ELUT
Earnings call transcript
2021 Q3
10 Nov 21
ELUT
Earnings call transcript
2021 Q2
10 Aug 21
Latest ownership filings
4
Matthew Ferguson
14 Mar 24
4/A
Matthew Strobeck
20 Feb 24
3/A
Matthew Strobeck
20 Feb 24
SC 13G/A
Birchview Capital, LP
20 Feb 24
SC 13G
Nantahala Capital Management, LLC
14 Feb 24
SC 13G/A
HIRSCHMAN ORIN
7 Feb 24
4
C Randal Mills
2 Feb 24
4
Matthew Ferguson
2 Feb 24
4
Michelle LeRoux Williams
2 Feb 24
SC 13D/A
HighCape Capital, L.P.
9 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 14.52 mm | 14.52 mm | 14.52 mm | 14.52 mm | 14.52 mm | 14.52 mm |
Cash burn (monthly) | (no burn) | (no burn) | 2.84 mm | 2.76 mm | 1.71 mm | 1.49 mm |
Cash used (since last report) | n/a | n/a | 16.95 mm | 16.52 mm | 10.21 mm | 8.93 mm |
Cash remaining | n/a | n/a | -2.43 mm | -2.00 mm | 4.31 mm | 5.59 mm |
Runway (months of cash) | n/a | n/a | -0.9 | -0.7 | 2.5 | 3.7 |
Institutional ownership, Q3 2023
97.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 23 |
Opened positions | 9 |
Closed positions | 4 |
Increased positions | 4 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 6.34 bn |
Total shares | 19.50 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
HighCape Capital | 7.83 mm | $11.98 mm |
Highcape Partners | 4.86 mm | $27.47 mm |
Hirschman Orin | 1.87 mm | $2.32 mm |
AIGH Capital Management | 1.76 mm | $2.30 bn |
Nantahala Capital Management | 1.65 mm | $2.36 bn |
Alyeska Investment | 663.24 k | $942.48 mm |
Perkins Capital Management | 347.20 k | $496.00 k |
Vanguard | 253.37 k | $362.33 mm |
Geode Capital Management | 69.64 k | $99.62 mm |
Knollwood Investment Advisory | 58.96 k | $84.32 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Mar 24 | Matthew Ferguson | Class A Common Stock | Payment of exercise | Dispose F | No | No | 3.24 | 528 | 1.71 k | 121,279 |
8 Mar 24 | Matthew Ferguson | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 1,288 | 0.00 | 121,807 |
8 Mar 24 | Matthew Ferguson | RSU Class A Common Stock | Option exercise | Dispose M | No | No | 0 | 1,288 | 0.00 | 1,287 |
31 Jan 24 | C Randal Mills | RSU Class A Common Stock | Grant | Acquire A | No | No | 0 | 487,500 | 0.00 | 487,500 |
31 Jan 24 | C Randal Mills | Stock Option Class A Common Stock | Grant | Acquire A | No | No | 3.61 | 487,500 | 1.76 mm | 487,500 |
31 Jan 24 | C Randal Mills | Stock Option Class A Common Stock | Sale back to company | Dispose D | No | No | 6.39 | 182,511 | 1.17 mm | 0 |
31 Jan 24 | C Randal Mills | RSU Class A Common Stock | Sale back to company | Dispose D | No | No | 0 | 89,894 | 0.00 | 0 |
31 Jan 24 | C Randal Mills | Stock Option Class A Common Stock | Grant | Acquire A | No | No | 3.61 | 182,511 | 658.86 k | 182,511 |
31 Jan 24 | C Randal Mills | RSU Class A Common Stock | Grant | Acquire A | No | No | 0 | 89,894 | 0.00 | 89,894 |
28 Dec 23 | HighCape Capital | Class A Common Stock | Other | Dispose J | Yes | No | 0 | 1,436,077 | 0.00 | 6,998,655 |
Press releases
Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM® Clearance Decision in First Half of 2024
7 Mar 24
Elutia's CanGarooRM: Pioneering Drug-Eluting Biologic for Secure Medical Implants
20 Feb 24
Elutia Regains Compliance with Nasdaq Listing Requirements
10 Jan 24